Bioviser Pharma Consulting Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 15.77%
- Profit Growth -172.49%
- Ebitda -140.96%
- Net Worth -115.87%
- Total Assets 105.57%
About Bioviser Pharma Consulting
Bioviser Pharma Consulting Private Limited (BPCPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 August 2019 (Five years and five months 21 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ivan Dsouza and Santhosh Sirupa serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U85310MH2019PTC329217
- Company No.
329217
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Bioviser Pharma Consulting?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santhosh Sirupa  | Director | 10-Aug-2019 | Current |
| Ivan Dsouza | Director | 10-Aug-2019 | Current |
Financial Performance of Bioviser Pharma Consulting.
Bioviser Pharma Consulting Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.77% increase. The company also saw a substantial fall in profitability, with a 172.49% decrease in profit. The company's net worth observed a substantial decline by a decrease of 115.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioviser Pharma Consulting?
Unlock access to Bioviser Pharma Consulting's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Iwana Consultancy Solutions Private LimitedIvan Dsouza is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioviser Pharma Consulting?
Unlock and access historical data on people associated with Bioviser Pharma Consulting, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioviser Pharma Consulting, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioviser Pharma Consulting's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
